Longevity PapersAbout
← All papers
RESEARCH PAPER / 2025-02-15

MicroRNA-34a suppresses KLF2 to promote pathological angiogenesis through the CXCR4/CXCL12 pathway in age-related macular degeneration

Colasanti, J. J., Lin, J. B., Terao, R., Lee, T. J., Santeford, A., Apte, R. S.

Washington University School of Medicine in St. LouisWashington University School of Medicine in St. Louis · biorxiv

Abstract

Age-related macular degeneration (AMD), characterized by pathologic choroidal neovascularization (CNV), is a leading cause of vision loss in the elderly. Vascular endothelial growth factor A (VEGFa) antagonists can prevent acute vision loss, but high treatment burden and loss of efficacy with chronic therapy highlight the need to explore alternative mechanisms. Recently, microRNA-34a (miR-34a) has emerged as a key regulator in aging and age-related diseases, but its role in neovascular AMD is unclear. In an injury-induced murine CNV model, we discovered miR-34a promoted pathological angiogenesis, without altering expression of Vegfa or its receptor Kdr, the canonical regulators of CNV. Mechanistically, miR-34a directly targets and inhibits the transcription factor KLF2 thereby upregulating the pro-angiogenic factors CXCR4 and CXCL12. Finally, we show miR-34a exacerbates CNV in aged mice and is expressed in CNV lesions excised from wet AMD patients. These findings establish a causal link between the age-related miR-34a and neovascularization in AMD.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

MicroRNA-34a promotes pathological angiogenesis in age-related macular degeneration by suppressing KLF2 and upregulating CXCR4/CXCL12. The study addresses a mechanism related to aging and age-related diseases, specifically focusing on the role of microRNA in pathological processes associated with AMD, which is a significant concern in the aging population.

Author of this paper? Send a correction.